RAS signalling in the colorectum in health and disease

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• RAS proteins function as molecular switches controlling cell growth, differentiation, and survival.
• Activating mutations in RAS proto-oncogenes yield oncogenic RAS proteins, driving cancer progression.
• KRAS mutations are prevalent in 40-50% of colorectal cancers, significantly influencing clinical management.

Purpose of the Study:

• To review KRAS signaling regulation in colorectal cancer.
• To discuss post-transcriptional and post-translational modifications of KRAS.
• To explore KRAS mutations and their implications for disease progression and therapy.

Main Methods:

• Literature review and synthesis of existing research on KRAS signaling.
• Analysis of genetic alterations and their functional consequences in colorectal cancer.
• Discussion of therapeutic strategies targeting KRAS.

Main Results:

• KRAS mutations significantly affect colorectal cancer patient survival and treatment response.
• The efficacy of anti-EGFR therapy is restricted to KRAS wild-type tumors.
• Understanding KRAS regulation and alterations is crucial for effective cancer treatment.

Conclusions:

• KRAS signaling pathways are critical in colorectal cancer development and progression.
• Targeted therapies must consider KRAS mutational status for optimal patient benefit.
• Further research into KRAS modifications and targeted interventions is warranted.